Journal of Clinical Pediatrics ›› 2022, Vol. 40 ›› Issue (12): 899-904.doi: 10.12372/jcp.2022.22e0410
• Urinary System Disease • Previous Articles Next Articles
WANG Ren, XIA Zhengkun, ZHANG Pei, GAO Chunlin()
Received:
2022-03-23
Published:
2022-12-15
Online:
2022-12-06
Contact:
GAO Chunlin
E-mail:shuangmu34@163.com
WANG Ren, XIA Zhengkun, ZHANG Pei, GAO Chunlin. Clinical and prognostic significance of glomerular C3 deposition in children with primary membranous nephropathy[J].Journal of Clinical Pediatrics, 2022, 40(12): 899-904.
"
项 目 | LI组(n=92) | HI组(n=121) | 统计量 | P |
---|---|---|---|---|
年龄[M(P25~P75)]/岁 | 15.0(12.3~16.0) | 16.0(14.0~17.0) | Z=3.23 | 0.001 |
男性[n(%)] | 47(51.1) | 72(59.5) | χ2=1.50 | 0.220 |
收缩压[M(P25~P75)]/mmHg | 120.0(110.0~126.0) | 120.0(110.0~130.0) | Z=0.43 | 0.667 |
舒张压[M(P25~P75)]/mmHg | 74.0(68.0~80.0) | 73.0(70.0~80.0) | Z=0.28 | 0.783 |
24 h尿蛋白定量[M(P25~P75)]/g·L-1 | 1.7(0.9~2.8) | 3.2(1.8~6.3) | Z=4.73 | <0.001 |
血尿[n(%)] | 54(58.7) | 90(74.4) | χ2=5.87 | 0.015 |
蛋白尿严重程度[n(%)] | χ2=14.10 | <0.001 | ||
大量蛋白尿 | 42(45.7) | 86(71.1) | ||
非大量蛋白尿 | 50(54.3) | 35(28.9) | ||
血清白蛋白(x±s)/g·L-1 | 34.4±7.7 | 28.4±6.1 | t=4.70 | <0.001 |
eGFR/ mL·min-1·1.73 m-2 | 166.0(141.7~198.3) | 149.9(137.7~181.0) | Z=2.35 | 0.019 |
病理分期[n(%)] | χ2=1.07 | 0.785 | ||
Ⅰ期 | 25(27.2) | 27(22.3) | ||
Ⅱ期 | 38(41.3) | 58(47.9) | ||
Ⅲ期 | 25(27.2) | 31(25.6) | ||
IV期 | 4(4.3) | 5(4.1) | ||
IgG染色强度[n(%)] | χ2=4.17 | 0.041 | ||
++ | 88(95.7) | 106(87.6) | ||
+++ | 4(4.3) | 15(12.4) | ||
IFTA分级[n(%)] | χ2=2.53 | 0.282 | ||
轻度 | 80(87.0) | 97(80.2) | ||
中度 | 1(1.1) | 5(4.1) | ||
重度 | 11(12.0) | 19(15.7) |
"
项 目 | LI组(n=92) | HI组(n=121) | 统计量 | P |
---|---|---|---|---|
随访时间[M(P25~P75)]/月 | 43.0(13.0~85.0) | 57.0(20.0~86.0) | Z=1.16 | 0.248 |
末次随访eGFR[M(P25~P75)]/mL·min-1·1.73 m-2 | 138.1(131.0~147.0) | 135.0(122.6~149.8) | Z=1.84 | 0.066 |
末次随访24h尿蛋白[M(P25~P75)]/g·L-1 | 0.4(0.3~2.1) | 0.6(0.3~3.1) | Z=1.18 | 0.237 |
治疗方案[n(%)] | ||||
他克莫司 | 35(38.0) | 47(38.8) | χ2=0.01 | 0.905 |
环磷酰胺 | 13(14.1) | 5(4.1) | χ2=6.75 | 0.009 |
吗替麦考酚酯 | 13(14.1) | 24(19.8) | χ2=1.19 | 0.276 |
利妥昔单抗 | 5(5.4) | 10(8.3) | χ2=0.64 | 0.424 |
保守治疗 | 32(34.8) | 42(34.7) | χ2=0.00 | 0.991 |
进展至ESRD(n) | 1(1.1) | 5(4.1) | χ2=0.83 | 0.362 |
转归[n(%)] | χ2=2.30 | 0.317 | ||
CR | 29(31.5) | 27(22.3) | ||
PR | 39(42.4) | 59(48.8) | ||
NR | 24(26.1) | 35(28.9) |
"
因 素 | 达ESRD时间(M±SE) | χ2值 | P | |
---|---|---|---|---|
性别 | 男 | 57.0±5.8 | 2.78 | 0.095 |
女 | 44.0±6.3 | |||
发病年龄 | ≤13岁 | 41.0±5.6 | 1.46 | 0.228 |
>13岁 | 58.7±6.1 | |||
血白蛋白 | ≤25 g·L-1 | 43.3±6.0 | 2.12 | 0.145 |
>25 g·L-1 | 57.8±7.4 | |||
基线eGFR | ≤90 mL·min-1·1.73 m-2 | 13.0±2.1 | 165.00 | <0.001 |
>90 mL·min-1·1.73 m-2 | 55.1±7.9 | |||
IgG染色强度 | ++ | 54.9±7.4 | 0.21 | 0.644 |
+++ | 46.4±5.6 | |||
C3染色强度 | <++ | 49.9±7.9 | 0.77 | 0.381 |
≥++ | 57.5±4.3 | |||
病理分期 | Ⅰ期 | 42.1±4.3 | 0.78 | 0.421 |
Ⅱ期 | 56.3±5.5 | |||
Ⅲ期 | 59.7±7.7 | |||
IV期 | 58.3±8.3 | |||
24 h尿蛋白定量 | <50 mg·kg-1 | 50.0±6.4 | 0.80 | 0.371 |
≥50 mg·kg-1 | 55.2±7.9 |
[1] |
Liu J, Zha Y, Zhang P, et al. The association between serum complement 4 and kidney disease progression in idiopathic membranous nephropathy: a multicenter retrospective cohort study[J]. Front Immunol, 2022, 13: 896654.
doi: 10.3389/fimmu.2022.896654 |
[2] |
Wang YN, Feng HY, Nie X, et al. Recent advances in clinical diagnosis and pharmacotherapy options of membranous nephropathy[J]. Front Pharmacol, 2022, 13: 907108.
doi: 10.3389/fphar.2022.907108 |
[3] | 中华医学会儿科学分会肾脏学组. 儿童激素敏感、复发/依赖肾病综合征诊治循证指南(2016)[J]. 中华儿科杂志, 2017, 55(10): 729-734. |
[4] | 王忍. 儿童原发性膜性肾病研究进展[J]. 临床儿科杂志, 2021, 39(7): 549-552. |
[5] |
Alsharhan L, Beck LJ. Membranous nephropathy: core curriculum 2021[J]. Am J Kidney Dis, 2021, 77(3): 440-453.
doi: 10.1053/j.ajkd.2020.10.009 pmid: 33487481 |
[6] |
Oto OA, Demir E, Mirioglu S, et al. Clinical significance of glomerular C3 deposition in primary membranous nephropathy[J]. J Nephrol, 2021, 34(2): 581-587.
doi: 10.1007/s40620-020-00915-w pmid: 33387338 |
[7] | 王楠楠. 儿童特发性膜性肾病诊疗进展[J]. 临床儿科杂志, 2021, 39(6): 476-480. |
[8] |
Fervenza FC, Glassock RJ. Molecular characterization of membranous nephropathy: quo vadis?[J]. J Am Soc Nephrol, 2022, 33(6): 1057-1059.
doi: 10.1681/ASN.2022040395 pmid: 35577559 |
[9] |
Teisseyre M, Cremoni M, Boyer-Suavet S, et al. Advances in the management of primary membranous nephropathy and rituximab-refractory membranous nephropathy[J]. Front Immunol, 2022, 13: 859419.
doi: 10.3389/fimmu.2022.859419 |
[10] |
Horvatic I, Ljubanovic DG, Bulimbasic S, et al. Prognostic significance of glomerular and tubulointerstitial morphometry in idiopathic membranous nephropathy[J]. Pathol Res Pract, 2012, 208(11): 662-667.
doi: 10.1016/j.prp.2012.08.004 pmid: 22995635 |
[11] |
Chinello C, de Haan N, Capitoli G, et al. Definition of IgG subclass-specific glycopatterns in idiopathic membranous nephropathy: aberrant IgG glycoforms in blood[J]. Int J Mol Sci, 2022, 23(9): 4664.
doi: 10.3390/ijms23094664 |
[12] |
Tsuboi N, Kawamura T, Miyazaki Y, et al. Low glomerular density is a risk factor for progression in idiopathic membranous nephropathy[J]. Nephrol Dial Transplant, 2011, 26: 3555-3560.
doi: 10.1093/ndt/gfr399 |
[13] |
Ponticelli C, Patrizia P, Del Vecchio L, et al. The evolution of the therapeutic approach to membranous nephropathy[J]. Nephrol Dial Transplant, 2021, 36: 768-773.
doi: 10.1093/ndt/gfaa014 |
[14] |
Yoshimoto K, Yokoyama H, Wada T, et al. Pathologic findings of initial biopsies reflect the outcomes of membranous nephropathy[J]. Kidney Int, 2004, 65(1): 148-153.
pmid: 14675045 |
[15] |
Cattran D. Management of membranous nephropathy: when and what for treatment[J]. J Am Soc Nephrol, 2005, 16(5): 1188-1194.
pmid: 15800117 |
[16] |
Sprangers B, Bomback AS, Cohen SD, et al. Idiopathic membranous nephropathy: clinical and histologic prognostic features and treatment patterns over time at a tertiary referral center[J]. Am J Nephrol, 2012, 36(1): 78-89.
doi: 10.1159/000339628 pmid: 22739228 |
[17] |
Spranger J, Homberg A, Sonnberger M, et al. Reporting guidelines for Delphi techniques in health sciences: a methodological review[J]. Z Evid Fortbild Qual Gesundhwes, 2022, 172: 1-11.
doi: 10.1016/j.zefq.2022.04.025 pmid: 35718726 |
[1] | LUO Mingjing, YU Jiaming, WANG Xiaodong, ZHANG Xiaoling, YU Yue, ZHANG Yu, WEN Feiqiu, LIU Sixi. Clinical analysis of invasive fungal disease secondary to allogeneic hematopoietic stem cell transplantation in 424 children with thalassemia [J]. Journal of Clinical Pediatrics, 2025, 43(1): 21-28. |
[2] | LIU Dongxia, JIN Rong, LIN Rongjun. Risk factors analysis of severe refractory Mycoplasma pneumoniae pneumonia complicated with bronchitis obliterans in children [J]. Journal of Clinical Pediatrics, 2025, 43(1): 29-34. |
[3] | ZHONG Jinhong, WANG Can, CHEN Fang. Progress in the research of infantile fiberoptic bronchoscopy sedation [J]. Journal of Clinical Pediatrics, 2025, 43(1): 50-55. |
[4] | JIANG Weiqin, WANG Jing, CHENG Anna, CHEN Tingting, HUANG Yujuan. Predictors of recurrent febrile seizures during the same febrile illness in children with febrile seizures [J]. Journal of Clinical Pediatrics, 2025, 43(1): 8-13. |
[5] | QIU Xiu, WEI Dongmei, LIN Shanshan, XIA Huimin, ZHOU Wenhao. Principles and practice of the Born in Guangzhou Cohort Study [J]. Journal of Clinical Pediatrics, 2024, 42(9): 747-752. |
[6] | FAN Jianxia. The origins and development of the healthy life trajectory program: a cohort of community-family-mother-child multidimensional interventions for overweight and obesity in children [J]. Journal of Clinical Pediatrics, 2024, 42(9): 768-773. |
[7] | JIANG Tao, LI Shuangjie, TANG Lian, OUYANG Wenxian. Immunobiological properties of peripheral blood MAIT cells in children with chronic hepatitis B [J]. Journal of Clinical Pediatrics, 2024, 42(9): 787-790. |
[8] | ZHOU Jie, LIU Keqiang, WANG Jinling, WANG Ying. Megacystis-microcolon-intestinal hypoperistalsis syndrome caused by MYH11 elongating mutation : a case report and literatures review [J]. Journal of Clinical Pediatrics, 2024, 42(9): 798-804. |
[9] | CHU Sijia, TANG Jihong. Research progress of central nervous system injury associated with pediatric acute lymphoblastic leukemia and its treatment [J]. Journal of Clinical Pediatrics, 2024, 42(9): 811-816. |
[10] | DING Yaping, XIA Shanshan, ZHANG Chenmei. Interpretation of “2023 Children’s Renal Nutrition Working Group Clinical Practice Recommendations: Nutritional Management of Children with Acute Kidney Injury” [J]. Journal of Clinical Pediatrics, 2024, 42(8): 667-672. |
[11] | LI Yirong, LI Huiping, GAO Jingyu, XIAO Yuhua, CHEN Xiaomin, LU Yanling, ZHAO Nana, FENG Xiaoqin. Comparison of different doses of cytarabine for induction chemotherapy in children with acute myeloid leukemia in FLAG-IDA regimen [J]. Journal of Clinical Pediatrics, 2024, 42(8): 673-677. |
[12] | HUANG Bo, DONG Yanying, SONG Linlan. Clinical characteristics of 348 children with infectious mononucleosis [J]. Journal of Clinical Pediatrics, 2024, 42(8): 678-683. |
[13] | WANG Dan, SHAO Jingbo, LI Hong, ZHANG Na, ZHU Jiashi, FU Pan, WANG Zhen. Clinical analysis of 38 cases of hematological malignancies complicated with tumor lysis syndrome in children [J]. Journal of Clinical Pediatrics, 2024, 42(8): 684-690. |
[14] | MA Yan, WEI Xingjiao, BAI Hua, ZHANG Yan, TIAN Xinmin, Aqsa Ahmad, LIANG Lijun. Analysis of etiological composition and clinical features of stage 5 chronic kidney disease in children in a tertiary hospital in western China [J]. Journal of Clinical Pediatrics, 2024, 42(8): 697-703. |
[15] | WANG Ye, ZHANG Linlin, CHI Zuofei, SUN Ruowen, JIANG Zehui, XU Gang. A case of clinical report of T-lymphoblastic lymphoma secondary to acute promyelocytic leukemia in children [J]. Journal of Clinical Pediatrics, 2024, 42(8): 722-727. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
Full text 342
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract 364
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Cited |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Shared | ||||||||||||||||||||||||||||||||||||||||||||||||||
|